SCHOTT Pharma Reports on First Year as Stand-Alone Company
SCHOTT Pharma is celebrating its first anniversary as a legally stand-alone company in the field of pharma drug containment solutions and delivery systems. The former pharma division of the SCHOTT Group has continued its profitable growth trajectory by supplying high-value solutions that enable pharma manufacturers to safely store and deliver life-saving drugs. In its first year the company has further enhanced its line of products, offering the broadest portfolio in the market and catering to the most important trends in the industry.
“From new drug categories that require deep-cold storage and more efficient production set-ups, to a shift from hospital to homecare treatments: Pharma companies around the world continue to trust SCHOTT Pharma to provide the ideal solution,” said Andreas Reisse, CEO.
The company’s strategy of delivering high-value solutions that cater to long-term trends in the pharma industry continues to be a key driver of profitability: in the first half of the fiscal year 2023, the company generated sales of €449 million, marking a strong 13.2% year-on-year growth.
“Our strategy of focusing on high-value solutions is paying off as the share of sales from high-margin, high-value solutions increased significantly to 45%,” commented Dr. Almuth Steinkühler, CFO.
As a global market leader with a pure-play focus on injectables, SCHOTT Pharma is represented in all major pharma hubs with 16 state-of-the-art production sites in Europe, North and Latin America, as well as Asia. The company produces around 13 billion prefillable glass and polymer syringes, cartridges, vials and ampoules each year.
